Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mitochondrial pharmacology: energy, injury and beyond</title><author><name sortKey="Davidson, S M" sort="Davidson, S M" uniqKey="Davidson S" first="S M" last="Davidson">S M Davidson</name><affiliation><nlm:aff id="au1"><institution>The Hatter Cardiovascular Institute, University College London</institution><addr-line>London, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lopaschuk, G D" sort="Lopaschuk, G D" uniqKey="Lopaschuk G" first="G D" last="Lopaschuk">G D Lopaschuk</name><affiliation><nlm:aff id="au2"><institution>Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta</institution><addr-line>Edmonton, AB, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Spedding, M" sort="Spedding, M" uniqKey="Spedding M" first="M" last="Spedding">M. Spedding</name><affiliation><nlm:aff id="au3"><institution>Spedding research solutions SARK</institution><addr-line>Le Vestnet, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Beart, P M" sort="Beart, P M" uniqKey="Beart P" first="P M" last="Beart">P M Beart</name><affiliation><nlm:aff id="au4"><institution>Florey Institute of Neuroscience and Mental Health, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="au5"><institution>Department of Pharmacology, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24684388</idno><idno type="pmc">3976605</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976605</idno><idno type="RBID">PMC:3976605</idno><idno type="doi">10.1111/bph.12679</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001283</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001283</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mitochondrial pharmacology: energy, injury and beyond</title><author><name sortKey="Davidson, S M" sort="Davidson, S M" uniqKey="Davidson S" first="S M" last="Davidson">S M Davidson</name><affiliation><nlm:aff id="au1"><institution>The Hatter Cardiovascular Institute, University College London</institution><addr-line>London, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lopaschuk, G D" sort="Lopaschuk, G D" uniqKey="Lopaschuk G" first="G D" last="Lopaschuk">G D Lopaschuk</name><affiliation><nlm:aff id="au2"><institution>Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta</institution><addr-line>Edmonton, AB, Canada</addr-line></nlm:aff></affiliation></author><author><name sortKey="Spedding, M" sort="Spedding, M" uniqKey="Spedding M" first="M" last="Spedding">M. Spedding</name><affiliation><nlm:aff id="au3"><institution>Spedding research solutions SARK</institution><addr-line>Le Vestnet, France</addr-line></nlm:aff></affiliation></author><author><name sortKey="Beart, P M" sort="Beart, P M" uniqKey="Beart P" first="P M" last="Beart">P M Beart</name><affiliation><nlm:aff id="au4"><institution>Florey Institute of Neuroscience and Mental Health, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="au5"><institution>Department of Pharmacology, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">British Journal of Pharmacology</title><idno type="ISSN">0007-1188</idno><idno type="eISSN">1476-5381</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>While the mitochondrion has long fascinated biologists and the sheer diversity of druggable targets has made it attractive for potential drug development, there has been little success translatable to the clinic. Given the diversity of inborn errors of metabolism and mitochondrial diseases, mitochondrially mediated oxidative stress (myopathies, reperfusion injury, Parkinson's disease, ageing) and the consequences of disturbed energetics (circulatory shock, diabetes, cancer), the potential for meaningful gain with novel drugs targeting mitochondrial mechanisms is huge both in terms of patient quality of life and health care costs. In this themed issue of the <italic>British Journal of Pharmacology</italic>, we highlight the key directions of the contemporary advances in the field of mitochondrial biology, emerging drug targets and new molecules which are close to clinical application. Authors' contributions are diverse both in terms of species and organs in which the mitochondrially related studies are performed, and from the perspectives of mechanisms under study. Defined roles of mitochondria in disease are updated and previously unknown contributions to disease are described in terms of the interface between basic science and pathological relevance.</p><sec><title>Linked Articles</title><p>This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.2014.171.issue-8">http://dx.doi.org/10.1111/bph.2014.171.issue-8</ext-link></p></sec></div></front></TEI><pmc article-type="editorial"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id><journal-id journal-id-type="publisher-id">bph</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24684388</article-id><article-id pub-id-type="pmc">3976605</article-id><article-id pub-id-type="doi">10.1111/bph.12679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Themed Issue: Mitochondrial Pharmacology: Energy, Injury & Beyond</subject></subj-group></article-categories><title-group><article-title>Mitochondrial pharmacology: energy, injury and beyond</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>S M</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopaschuk</surname><given-names>G D</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spedding</surname><given-names>M</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Beart</surname><given-names>P M</given-names></name><xref ref-type="aff" rid="au4">4</xref><xref ref-type="aff" rid="au5">5</xref></contrib><aff id="au1"><label>1</label><institution>The Hatter Cardiovascular Institute, University College London</institution><addr-line>London, UK</addr-line></aff><aff id="au2"><label>2</label><institution>Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta</institution><addr-line>Edmonton, AB, Canada</addr-line></aff><aff id="au3"><label>3</label><institution>Spedding research solutions SARK</institution><addr-line>Le Vestnet, France</addr-line></aff><aff id="au4"><label>4</label><institution>Florey Institute of Neuroscience and Mental Health, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></aff><aff id="au5"><label>5</label><institution>Department of Pharmacology, University of Melbourne</institution><addr-line>Parkville, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Philip M Beart, Department of Florey Neuroscience, University of Melbourne, Genetics lane, Royal Parade, Parkville Vic 3052, Australia. E-mail: <email>philip.beart@florey.edu.au</email>;, Sean Davidson, Sean M Davidson, The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK. E-mail: <email>s.davidson@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2014</year></pub-date><volume>171</volume><issue>8</issue><fpage>1795</fpage><lpage>1797</lpage><permissions><copyright-statement>© 2014 The British Pharmacological Society</copyright-statement><copyright-year>2014</copyright-year></permissions><abstract><p>While the mitochondrion has long fascinated biologists and the sheer diversity of druggable targets has made it attractive for potential drug development, there has been little success translatable to the clinic. Given the diversity of inborn errors of metabolism and mitochondrial diseases, mitochondrially mediated oxidative stress (myopathies, reperfusion injury, Parkinson's disease, ageing) and the consequences of disturbed energetics (circulatory shock, diabetes, cancer), the potential for meaningful gain with novel drugs targeting mitochondrial mechanisms is huge both in terms of patient quality of life and health care costs. In this themed issue of the <italic>British Journal of Pharmacology</italic>, we highlight the key directions of the contemporary advances in the field of mitochondrial biology, emerging drug targets and new molecules which are close to clinical application. Authors' contributions are diverse both in terms of species and organs in which the mitochondrially related studies are performed, and from the perspectives of mechanisms under study. Defined roles of mitochondria in disease are updated and previously unknown contributions to disease are described in terms of the interface between basic science and pathological relevance.</p><sec><title>Linked Articles</title><p>This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.2014.171.issue-8">http://dx.doi.org/10.1111/bph.2014.171.issue-8</ext-link></p></sec></abstract><kwd-group><kwd>mitochondria</kwd><kwd>energetics</kwd><kwd>cell death</kwd><kwd>mitochondrial diseases</kwd><kwd>models for mitochondrial disorders</kwd><kwd>drug targets</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001283 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001283 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |